Clinical trials: Influenza
Influenza A
Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge
The purpose of this study is to assess the safety, tolerability, efficacy, and immunogenicity of an influenza A vaccine (vaccine: FP-01.1), as compared to placebo, in healthy volunteers following a dose of influenza A virus.
- Trial name
- NCT02071329
- Testing
- Vaccine FP-01.1, Virus Challenge
- Where
- United Kingdom
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children
The present study is designed to evaluate in children (aged between 3 and 9 years) the immunogenicity and safety of different antigen doses of the candidate vaccine (GSK1562902A) administered following a two-administration…
- Trial name
- NCT00502593
- Testing
- Pandemic Influenza Vaccine (GSK1562902A), Fluarix™
- Where
- 7 sites in Spain
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults
The aim of this trial is to evaluate the safety and immunogenicity of the 2014-2015 formulations of Fluzone® Quadrivalent and Fluzone® Intradermal vaccines in adults 18 to < 65 years or age, and of the 2014-2015 formulations of…
- Trial name
- NCT02258334
- Testing
- Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
- Where
- 4 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07121192
- Testing
- Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1
- Where
- 22 sites in United States
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Respiratory Infection, Influenza
Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld…
- Trial name
- LIGHT (NCT07610967)
- Testing
- RD-X19
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- David Moss
Influenza
H5 Vaccine Alone or With Adjuvant in Healthy Adults
This randomized, controlled, double-blinded, dose-ranging, Phase I-II study in 600 healthy adults, 18 to 49 years old, is designed to investigate the safety, reactogenicity, and dose-related immunogenicity of an investigational…
- Trial name
- NCT00296634
- Testing
- Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
- Where
- 4 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
This study is a multi-center, randomized, double-blind Phase III clinical trial. The aim of the study is to describe the immunogenicity and safety of the quadrivalent cell culture-derived influenza vaccine compared to the…
- Trial name
- NCT02621164
- Testing
- NBP607-QIV, Agrippal S1
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Influenza
pH1N1 Blinded Challenge Study
This protocol describes a clinical trial to develop and validate a Controlled Human Infection Model (CHIM) for influenza A/Arkansas/08/2020 (pH1N1).
- Trial name
- NCT07110532
- Testing
- A/Arkansas/08/2020 (pH1N1)
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal
This study will provide the Senegal Ministry of Health with data on the clinical efficacy of the Live-Attenuated Influenza Vaccine (LAIV). This data will inform future policy considerations for influenza vaccine.
- Trial name
- NCT01854632
- Testing
- SIIL Live Attenuated Influenza Vaccine
- Where
- Senegal
- Volunteers
- 1,761 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
The purpose of this study is to see how much antibody (proteins produced by the immune system that help fight infections) the body makes after getting a flu vaccine.
- Trial name
- NCT01173211
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pandemic Influenza Vaccine, Prevention
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
- Conditions
- Pandemic Influenza Vaccine, Prevention, Pandemic Influenza
- Trial name
- NCT00660257
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months
Multi-center, observational, active safety surveillance study in participants aged 6 to 35 months in Korea under routine clinical practices.
- Trial name
- NCT05832333
- Testing
- VaxigripTetra®
- Where
- 12 sites in South Korea
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Two-site Intradermal Influenza Vaccination in Elderly
One-site dose sparing intradermal influenza vaccination in elderly had been studied but resulted in unsatisfactory outcomes. The investigators evaluate the safety and immunogenicity of the two-site intradermal injection of…
- Trial name
- NCT01202552
- Testing
- seasonal influenza vaccine
- Where
- Thailand
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Influenza, Community-acquired Pneumonia
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain…
- Conditions
- Influenza, Community-acquired Pneumonia, Cardiovascular Events
- Trial name
- NCT06029933
- Testing
- Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
- Where
- United States
- Volunteers
- 1,500,000 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Influenza
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age.
- Trial name
- NCT01439360
- Testing
- Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A, Havrix Junior, Prevenar 13
- Where
- 103 sites in Bangladesh, Belgium and 11 more
- Volunteers
- 12,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Vaccine
Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China
This study evaluates the safety of the quadrivalent subunit influenza vaccine in individuals aged 3 years and older in Jiangsu Province, China.
- Trial name
- NCT07710586
- Testing
- quadrivalent subunit influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 3,105 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Healthy Volunteers
Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00346723
- Testing
- Influvac® subunit influenza vaccine for i.m./deep s.c.injection
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged 18 to 64 years
- Trial name
- NCT00695669
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2010/2011 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01306305
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
SARS-CoV-2, Seasonal Influenza
A Study of Modified mRNA Vaccines in Healthy Adults
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Trial name
- NCT05397223
- Testing
- mRNA-1273, mRNA-1010, mRNA-1345
- Where
- 8 sites in United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.